Inflammatory Related Cardiovascular Diseases: From Molecular Mechanisms to Therapeutic Targets

Author(s): Celestino Sardu*, Giuseppe Paolisso, Raffaele Marfella

Journal Name: Current Pharmaceutical Design

Volume 26 , Issue 22 , 2020


Become EABM
Become Reviewer
Call for Editor

Abstract:

Inflammation is a pathogenic response to multiple factors, that causes over-activation of different molecules and pro-inflammatory cellular lines. Different behavioral factors and risk factors might enhance the inflammatory stress, and this might cause cardiovascular disease (CVD). CVD is the world’s leading cause of morbidity and mortality, and it is represented by hypertension, coronary heart disease, cerebrovascular disease, peripheral vascular disease, heart failure, rheumatic heart disease, congenital heart disease and cardiomyopathies. In this context, inflammation is both a cause and an aggravating factor in CVD, as well as a mediator of its worst prognostic. The mechanisms that link inflammation to CVD are multiple, complex and multi-factorial. To date, the role of inflammation in the genesis and progression of CVD has been extensively analyzed in recent studies. However, in the last decades, new biomarkers are joining the already known inflammatory biomarkers, such as Creactive protein, interleukins, tumor necrosis factor alpha and nitrotyrosine. Among these new biomarkers, we have to report sirtuins, microRNAs, ST2 protein, apolipoprotein E protein, adiponectin, and others. These biomarkers are preferentially expressed locally in the target tissue of inflammation, but also released in peripheral blood and then used as diagnostic and prognostic biomarkers. Indeed, these biomarkers might also predict future adverse cardiovascular events and worse prognosis in patients with CVD. Furthermore, these new inflammatory biomarkers can also be analyzed to evaluate therapeutic efficacy in patients with CVD. Furthermore, this might open up new fields and interesting research concerning the link between inflammation and CVD.

Keywords: Inflammatory stress, cardiovascular diseases, risk factors, prevention, treatment, microRNAs.

[1]
Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000; 148(2): 209-14.
[http://dx.doi.org/10.1016/S0021-9150(99)00463-3] [PMID: 10657556]
[2]
Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004; 109: II-2-II-10.
[3]
Braunwald E. Shattuck lecture--cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 1997; 337(19): 1360-9.
[http://dx.doi.org/10.1056/NEJM199711063371906] [PMID: 9358131]
[4]
Roth GA, Johnson C, Abajobir A, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol 2017; 70(1): 1-25.
[http://dx.doi.org/10.1016/j.jacc.2017.04.052] [PMID: 28527533]
[5]
Townsend N, Wilson L, Bhatnagar P, Wickramasinghe K, Rayner M, Nichols M. Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J 2016; 37(42): 3232-45.
[http://dx.doi.org/10.1093/eurheartj/ehw334] [PMID: 27523477]
[6]
Ordovás JM, Smith CE. Epigenetics and cardiovascular disease. Nat Rev Cardiol 2010; 7(9): 510-9.
[http://dx.doi.org/10.1038/nrcardio.2010.104] [PMID: 20603647]
[7]
Lefkowitz RJ, Willerson JT. Prospects for cardiovascular research. JAMA 2001; 285(5): 581-7.
[http://dx.doi.org/10.1001/jama.285.5.581] [PMID: 11176863]
[8]
Ruan Y, Guo Y, Zheng Y, et al. Cardiovascular disease (CVD) and associated risk factors among older adults in six low-and middle-income countries: results from SAGE Wave 1. BMC Public Health 2018; 18(1): 778.
[http://dx.doi.org/10.1186/s12889-018-5653-9] [PMID: 29925336]
[9]
Sardu C, Pieretti G, D’Onofrio N, et al. Inflammatory cytokines and SIRT1 levels in subcutaneous abdominal fat: relationship with cardiac performance in overweight pre-diabetics patients. Front Physiol 2018; 9: 1030.
[http://dx.doi.org/10.3389/fphys.2018.01030] [PMID: 30246793]
[10]
D'Onofrio N, Pieretti G, Ciccarelli F, et al. Abdominal fat SIRT6 expression and its relationship with inflammatory and metabolic pathways in pre-diabetic overweight patients Int J Mol Sci 2019: 6; 20(5): 1153.
[http://dx.doi.org/10.3390/ijms20051153]
[11]
D’Onofrio N, Sardu C, Paolisso P, et al. MicroRNA-33 and SIRT1 influence the coronary thrombus burden in hyperglycemic STEMI patients. J Cell Physiol 2020; 235(2): 1438-52.
[http://dx.doi.org/10.1002/jcp.29064] [PMID: 31294459]
[12]
Sardu C, Marfella R, Santamaria M, et al. Stretch, injury and inflammation markers evaluation to predict clinical outcomes after implantable cardioverter defibrillator therapy in heart failure patients with metabolic syndrome. Front Physiol 2018; 9(9): 758.
[http://dx.doi.org/10.3389/fphys.2018.00758] [PMID: 29997521]
[13]
Sasso FC, Pafundi PC, Marfella R, et al. Adiponectin and insulin resistance are related to restenosis and overall new PCI in subjects with normal glucose tolerance: the prospective AIRE Study. Cardiovasc Diabetol 2019; 18(1): 24.
[http://dx.doi.org/10.1186/s12933-019-0826-0] [PMID: 30832662]
[14]
Messner B, Bernhard D. Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis. Arterioscler Thromb Vasc Biol 2014; 34(3): 509-15.
[http://dx.doi.org/10.1161/ATVBAHA.113.300156] [PMID: 24554606]
[15]
Inoue-Choi M, Liao LM, Reyes-Guzman C, Hartge P, Caporaso N, Freedman ND. Association of long-term, low-intensity smoking with all-cause and cause-specific mortality in the national institutes of Health-AARP diet and health study. JAMA Intern Med 2017; 177(1): 87-95.
[http://dx.doi.org/10.1001/jamainternmed.2016.7511] [PMID: 27918784]
[16]
Gambardella J, Sardu C, Sacra C, Del Giudice C, Santulli G. Quit smoking to outsmart atherogenesis: Molecular mechanisms underlying clinical evidence. Atherosclerosis 2017; 257: 242-5.
[http://dx.doi.org/10.1016/j.atherosclerosis.2016.12.010] [PMID: 28108018]
[17]
Frey P, Waters DD, DeMicco DA, et al. Impact of smoking on cardiovascular events in patients with coronary disease receiving contemporary medical therapy (from the Treating to New Targets [TNT] and the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] trials). Am J Cardiol 2011; 107(2): 145-50.
[http://dx.doi.org/10.1016/j.amjcard.2010.09.006] [PMID: 21129718]
[18]
Galland L. Diet and inflammation. Nutr Clin Pract 2010; 25(6): 634-40.
[http://dx.doi.org/10.1177/0884533610385703] [PMID: 21139128]
[19]
Petersson H, Lind L, Hulthe J, Elmgren A, Cederholm T, Risérus U. Relationships between serum fatty acid composition and multiple markers of inflammation and endothelial function in an elderly population. Atherosclerosis 2009; 203(1): 298-303.
[http://dx.doi.org/10.1016/j.atherosclerosis.2008.06.020] [PMID: 18687433]
[20]
Andersson J, Jansson JH, Hellsten G, Nilsson TK, Hallmans G, Boman K. Effects of heavy endurance physical exercise on inflammatory markers in non-athletes. Atherosclerosis 2010; 209(2): 601-5.
[http://dx.doi.org/10.1016/j.atherosclerosis.2009.10.025] [PMID: 19954777]
[21]
Colbert LH, Visser M, Simonsick EM, et al. Physical activity, exercise, and inflammatory markers in older adults: findings from the Health, Aging and Body Composition Study. J Am Geriatr Soc 2004; 52(7): 1098-104.
[http://dx.doi.org/10.1111/j.1532-5415.2004.52307.x] [PMID: 15209647]
[22]
Lucas DL, Brown RA, Wassef M, Giles TD. Alcohol and the cardiovascular system: research challenges and opportunities. J Am Coll Cardiol 2005; 45(12): 1916-24.
[http://dx.doi.org/10.1016/j.jacc.2005.02.075] [PMID: 15963387]
[23]
Walsh CR, Larson MG, Evans JC, et al. Alcohol consumption and risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med 2002; 136(3): 181-91.
[http://dx.doi.org/10.7326/0003-4819-136-3-200202050-00005] [PMID: 11827493]
[24]
Djoussé L, Levy D, Benjamin EJ, et al. Long-term alcohol consumption and the risk of atrial fibrillation in the Framingham Study. Am J Cardiol 2004; 93(6): 710-3.
[http://dx.doi.org/10.1016/j.amjcard.2003.12.004] [PMID: 15019874]
[25]
Quertemont E. Genetic polymorphism in ethanol metabolism: acetaldehyde contribution to alcohol abuse and alcoholism. Mol Psychiatry 2004; 9(6): 570-81.
[http://dx.doi.org/10.1038/sj.mp.4001497] [PMID: 15164086]
[26]
Fernández-Solà J, Nicolás JM, Oriola J, et al. Angiotensin-converting enzyme gene polymorphism is associated with vulnerability to alcoholic cardiomyopathy. Ann Intern Med 2002; 137(5 Part 1): 321-6.
[http://dx.doi.org/10.7326/0003-4819-137-5_Part_1-200209030-00007] [PMID: 12204015]
[27]
Pochmalicki G, Genest M, Jibril H. Late ventricular potentials and heavy drinking. Heart 1997; 78(2): 163-5.
[http://dx.doi.org/10.1136/hrt.78.2.163] [PMID: 9326991]
[28]
Emberson JR, Bennett DA. Effect of alcohol on risk of coronary heart disease and stroke: causality, bias, or a bit of both? Vasc Health Risk Manag 2006; 2(3): 239-49.
[http://dx.doi.org/10.2147/vhrm.2006.2.3.239] [PMID: 17326330]
[29]
Reynolds K, Lewis B, Nolen JD, Kinney GL, Sathya B, He J. Alcohol consumption and risk of stroke: a meta-analysis. JAMA 2003; 289(5): 579-88.
[http://dx.doi.org/10.1001/jama.289.5.579] [PMID: 12578491]
[30]
Muth ND, Laughlin GA, von Mühlen D, Smith SC, Barrett-Connor E. High-density lipoprotein subclasses are a potential intermediary between alcohol intake and reduced risk of cardiovascular disease: the Rancho Bernardo Study. Br J Nutr 2010; 104(7): 1034-42.
[http://dx.doi.org/10.1017/S0007114510001595] [PMID: 20426890]
[31]
Overvad TF, Rasmussen LH, Skjøth F, et al. Alcohol intake and prognosis of atrial fibrillation. Heart 2013; 99(15): 1093-9.
[http://dx.doi.org/10.1136/heartjnl-2013-304036] [PMID: 23766449]
[32]
Rantakömi SH, Kurl S, Sivenius J, Kauhanen J, Laukkanen JA. The frequency of alcohol consumption is associated with the stroke mortality. Acta Neurol Scand 2014; 130(2): 118-24.
[http://dx.doi.org/10.1111/ane.12243] [PMID: 24606050]
[33]
Piano MR, Phillips SA. Alcoholic cardiomyopathy: pathophysiologic insights. Cardiovasc Toxicol 2014; 14(4): 291-308.
[http://dx.doi.org/10.1007/s12012-014-9252-4] [PMID: 24671642]
[34]
Matsumoto C, Miedema MD, Ofman P, Gaziano JM, Sesso HD. An expanding knowledge of the mechanisms and effects of alcohol consumption on cardiovascular disease. J Cardiopulm Rehabil Prev 2014; 34(3): 159-71. Inflammatory Related Cardiovascular Diseases: From Molecular Mechanisms Current Pharmaceutical Design, 2020, Vol. 26, No. 22 2573
[http://dx.doi.org/10.1097/HCR.0000000000000042] [PMID: 24667667]
[35]
Zhang Y, Post WS, Dalal D, Blasco-Colmenares E, Tomaselli GF, Guallar E. Coffee, alcohol, smoking, physical activity and QT interval duration: results from the Third National Health and Nutrition Examination Survey. PLoS One 2011; 6(2)e17584
[http://dx.doi.org/10.1371/journal.pone.0017584] [PMID: 21386989]
[36]
Kjeldsen SE. Hypertension and cardiovascular risk: General aspects. Pharmacol Res 2018; 129: 95-9.
[http://dx.doi.org/10.1016/j.phrs.2017.11.003] [PMID: 29127059]
[37]
Solak Y, Afsar B, Vaziri ND, et al. Hypertension as an autoimmune and inflammatory disease. Hypertens Res 2016; 39(8): 567-73.
[http://dx.doi.org/10.1038/hr.2016.35] [PMID: 27053010]
[38]
Syed MA, Barinas-Mitchell E, Pietropaolo SL, et al. Is type 2 diabetes a chronic inflammatory/autoimmune disease? Diabetes Nutr Metab 2002; 15(2): 68-83.
[PMID: 12059095]
[39]
Centers for Disease Control and Prevention National diabetes statistics report: Estimates of diabetes and its burden in the United States, 2014. Atlanta, GA: US Department of Health and Human Services 2017.
[40]
Sardu C, Paolisso P, Sacra C, et al. Effects of metformin therapy on coronary endothelial dysfunction in patients with prediabetes with stable angina and nonobstructive coronary artery stenosis: The CODYCE multicenter prospective study. Diabetes Care 2019; 42(10): 1946-55.
[http://dx.doi.org/10.2337/dc18-2356] [PMID: 30796109]
[41]
Sardu C, Barbieri M, Balestrieri ML, et al. Thrombus aspiration in hyperglycemic ST-elevation myocardial infarction (STEMI) patients: clinical outcomes at 1-year follow-up. Cardiovasc Diabetol 2018; 17(1): 152.
[http://dx.doi.org/10.1186/s12933-018-0795-8] [PMID: 30497513]
[42]
Marfella R, Sardu C, Balestrieri ML, et al. Effects of incretin treatment on cardiovascular outcomes in diabetic STEMI-patients with culprit obstructive and multivessel non obstructive-coronary-stenosis. Diabetol Metab Syndr 2018; 10: 1.
[http://dx.doi.org/10.1186/s13098-017-0304-3] [PMID: 29308090]
[43]
Marfella R, Sardu C, Calabrò P, et al. Non-ST-elevation myocardial infarction outcomes in patients with type 2 diabetes with non-obstructive coronary artery stenosis: Effects of incretin treatment. Diabetes Obes Metab 2018; 20(3): 723-9.
[http://dx.doi.org/10.1111/dom.13122] [PMID: 28950045]
[44]
Santulli G, Pagano G, Sardu C, et al. Calcium release channel RyR2 regulates insulin release and glucose homeostasis. J Clin Invest 2015; 125(5): 1968-78.
[http://dx.doi.org/10.1172/JCI79273] [PMID: 25844899]
[45]
Sardu C, Carreras G, Katsanos S, et al. Metabolic syndrome is associated with a poor outcome in patients affected by outflow tract premature ventricular contractions treated by catheter ablation. BMC Cardiovasc Disord 2014; 14: 176.
[http://dx.doi.org/10.1186/1471-2261-14-176] [PMID: 25480761]
[46]
Sardu C, Barbieri M, Santamaria M, et al. Multipolar pacing by cardiac resynchronization therapy with a defibrillators treatment in type 2 diabetes mellitus failing heart patients: impact on responders rate, and clinical outcomes. Cardiovasc Diabetol 2017; 16(1): 75.
[http://dx.doi.org/10.1186/s12933-017-0554-2] [PMID: 28599667]
[47]
Sardu C, Paolisso P, Sacra C, et al. Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate. Cardiovasc Diabetol 2018; 17(1): 137.
[http://dx.doi.org/10.1186/s12933-018-0778-9] [PMID: 30348145]
[48]
Tietge UJ. Hyperlipidemia and cardiovascular disease: inflammation, dyslipidemia, and atherosclerosis. Curr Opin Lipidol 2014; 25(1): 94-5.
[http://dx.doi.org/10.1097/MOL.0000000000000051] [PMID: 24398450]
[49]
Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006; 6(7): 508-19.
[http://dx.doi.org/10.1038/nri1882] [PMID: 16778830]
[50]
Libby P, Ridker PM, Hansson GK. Leducq Transatlantic Network on Atherothrombosis Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009; 54(23): 2129-38.
[http://dx.doi.org/10.1016/j.jacc.2009.09.009] [PMID: 19942084]
[51]
Maseri A. Inflammation, atherosclerosis, and ischemic events -- exploring the hidden side of the moon. N Engl J Med 1997; 336(14): 1014-6.
[http://dx.doi.org/10.1056/NEJM199704033361409] [PMID: 9077383]
[52]
Sardu C, Santulli G, Santamaria M, et al. Effects of alpha lipoic acid on multiple cytokines and biomarkers and recurrence of atrial fibrillation within 1 year of catheter ablation. Am J Cardiol 2017; 119(9): 1382-6.
[http://dx.doi.org/10.1016/j.amjcard.2017.01.040] [PMID: 28258730]
[53]
Ridker PM, Everett BM, Thuren T, et al. CANTOS Trial Group Anti inflammatory therapy with canakinumab for atherosclerotic disease. CANTOS trial. N Engl J Med 2017; 377(12): 1119-31.
[http://dx.doi.org/10.1056/NEJMoa1707914] [PMID: 28845751]
[54]
Ridker PM, Everett BM, Pradhan A, et al. CIRT investigators. N Engl J Med 2019; 380: 752-62.
[http://dx.doi.org/10.1056/NEJMoa1809798] [PMID: 30415610]
[55]
Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med 2019. Epub ahead of print
[http://dx.doi.org/10.1056/NEJMoa1912388] [PMID: 31733140]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 26
ISSUE: 22
Year: 2020
Published on: 04 July, 2020
Page: [2565 - 2573]
Pages: 9
DOI: 10.2174/1381612826666200213123029
Price: $65

Article Metrics

PDF: 31
HTML: 5
PRC: 1